CBD or cannabidiol is one of the substances that are found in cannabis (marijuana).
CBD is legally available in the UK.
CBD is claimed to be effective in a variety of conditions including anxiety, insomnia, inflammatory disorders like Irritable Bowel Syndrome (IBS), as well as chronic pain conditions such as Fibromyalgia.
There is in fact a hypothesis that Fibromyalgia is driven by under stimulation of the body’s own cannabinoid receptor syndrome.
Our aim initially for the registry is to develop a robust, real-world, evidence base for full-spectrum CBD oil in Fibromyalgia.
(Full-spectrum CBD is cannabis with the THC component removed whilst the rest of the cannabis components remain, enabling the “entourage effect”).
Our ultimate goal is to produce sufficient evidence to enable full-spectrum CBD oil to be available on prescription.
Our oil is sourced from European plants that are GMO-free and do not contain unwanted additives or chemicals. It is produced to FSSC22000.
We are looking for 20 early assisters for the registry development. We can’t currently offer the oil for free, we wish we could, but this is currently beyond us.
We can however offer it to these early assistors at £32/$44, permanently, that’s half the normal retail price for 10% full-spectrum oil.
Involvement won’t be onerous or take up much of your time, maybe 15 minutes a month.
All you will need to do is send us data via a phone App on how you are feeling and what effect the full-spectrum CBD oil is having on your Fibromyalgia
As an additional way of thanks, anyone who becomes an early assister will have the opportunity of a 30-minute FREE Zoom 1-2-1 conversation about their Fibromyalgia with Dr. Ilan Lieberman, the founder of Fibroforward.
If you want to learn more or participate in the registry contact us. email@example.com
Please note this is NOT a clinical trial, we have not sought ethical permission, there is no placebo arm, no specific control group, we would never intend for individuals to consider participation as entry into any type of “drug trial”. The registry is intended to record the effects as the participant observes them of CBD on their quality of life in its various aspects with the particular type of CBD that we make available. In doing so we intend to develop a robust real-world evidence base for CBD use.
Further details of endocannabinoid deficiency syndrome are available in the following paper. For the avoidance of doubt neither the authors of this paper, the publisher, or the institutions the authors are involved with are in any way associated with this registry. The presentation of this reference is purely for the purpose of highlighting the hypothesis it describes.
Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes. Ethan B Russo. Cannabis Cannabinoid Res. 2016; 1(1): 154–165
& Thanks to Kimzey Nanney for her images